Hyderabad: City-based pharma player   Pharma Limited on Wednesday said the US Food and Drug Administration (FDA) has approved its marketing partner Mylan’s abbreviated new drug applications (ANDAs) for Glatiramer Acetate injections that are indicated for the treatment of patients suffering from relapsing forms of multiple sclerosis (MS).

 Mylan has got approval for Glatiramer Acetate 40 mg/ml for 3-times-a-week injection, which is a substitutable generic version of Teva's Copaxone 40 mg/ml, and Glatiramer Acetate injection 20 mg/ml for once-daily injection, a substitutable generic version of Teva’s Copaxone 20 mg/ml, Natco said. Natco said the launch plans for products will be communicated after concurring with Mylan. According to estimates, Copaxone is most prescribed treatment for relapsing forms of MS in the US with brand sales for 20 mg/ml dose at $700 million and $3.64 billion for 40 mg/ml dose for the 12 months ended July 31, 2017.
 
 
